Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunological study of Shingrix in diabetes and dialysis patients
jRCTs031240031Completed
- Sponsor
- GSK
- Start
- May 2024
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of Zoster vaccine recombinant in herpes zoster (HZ) (3 arms), sponsored by GSK. Primary endpoints: Vaccine response rate at 2 months, Vaccine response rate at 3 months and 2 more. Started May 2024; status: completed.
02
Drugs
Zoster vaccine recombinant
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on jRCTs031240031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031240031.